SARMs
MK-677 (Ibutamoren)
MK-677 is a growth hormone secretagogue with one of the longest research track records in the compound community. Below, we compare vendors currently stocking research-grade MK-677 — not just a single sales page.
MK-677 is a growth hormone secretagogue with one of the longest research track records in the compound community. Below, we compare vendors currently stocking research-grade MK-677 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 SwissChemsBest Value |
$69.95 | Third-party COA | Buy Here → | |
 Next Chem |
$71.95 (liquid solution) | Third-party COA | Auto-applied | Buy Here → |
 UK Sarms |
£59.99 | Third-party COA | Auto-applied | Buy Here → |
 Chemyo |
$79.99 (25mg/ml solution) | Third-party COA | Buy Here → |
MK-677 (Ibutamoren) is an orally active, non-peptide growth hormone secretagogue that mimics ghrelin's action at the GHS-R1a receptor. Unlike injectable peptide secretagogues, its oral bioavailability and long half-life have made it one of the most-discussed compounds in GH-research contexts.
Research-grade MK-677 is typically supplied as capsules, commonly at 10mg or 25mg per capsule in 60-count bottles, intended for laboratory research use only.
MK-677 activates the ghrelin receptor, stimulating pulsatile growth hormone release and, as a downstream effect, increased IGF-1 levels — a mechanism studied across multiple published human clinical trials examining its effects on the GH axis.
MK-677 has been studied in randomized controlled human trials for its ability to sustainably raise GH and IGF-1 levels over extended periods, giving it more human clinical data than many peptide secretagogues.
Published trials have also examined MK-677's effects on slow-wave sleep and lean body mass in older adults and in muscle-wasting populations, representing some of the better-documented clinical research in this compound category.
Published clinical trials have reported increased appetite, mild fluid retention, and increases in fasting blood glucose and reduced insulin sensitivity with sustained MK-677 use — findings that have been consistently replicated across studies and are an important consideration given its GH/IGF-1 mechanism. It is not FDA-approved for any indication.
Doses studied in published human clinical trials have varied by study objective and are documented in that trial literature; no FDA-approved human dosage exists for MK-677 outside those research contexts.
Compound X does not sell MK-677 (Ibutamoren) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
MK-677 clinical trial data is indexed on PubMed under "MK-677 Ibutamoren growth hormone secretagogue."
New guides, vendor comparisons and compound breakdowns every week.